MedTrace Logo

A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine

NCT06602479 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 488

Last updated 2026-05-19

No results posted yet for this study

Summary

The purpose of this Phase 2 study is to evaluate the safety and efficacy of SC MEDI0618 compared to placebo in participants with episodic migraine.

Conditions

Interventions

DRUG

MEDI0618

MEDI0618 per protocol

DRUG

Placebo

Volume-matched placebo for all arms

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-07
Primary Completion
2026-12-18
Completion
2027-05-07
FDA Drug
Yes

Countries

  • United States
  • Czechia
  • Denmark
  • Germany
  • Hungary
  • Italy
  • Poland
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06602479 on ClinicalTrials.gov